Abstracts tagged "neurologic involvement and patient outcomes"

Abstract Number: 671 • 2019 ACR/ARP Annual Meeting
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
John G Hanly¹, Qiuju Li ², Li Su ³, Murray Urowitz ⁴, Caroline Gordon ⁵, Sang-Cheol Bae ⁶, Juanita Romero-Diaz ⁷, Jorge Sanchez-Guerrero ⁸, Sasha Bernatsky ⁹, Ann E Clarke ¹⁰, Daniel J Wallace ¹¹, David A Isenberg ¹², Anisur Rahman ¹³, Joan Merrill ¹⁴, Paul Fortin ¹⁵, Dafna Gladman ¹⁶, Ian Bruce ¹⁷, Michelle Petri ¹⁸, Ellen M Ginzler ¹⁹, MA Dooley ²⁰, Kristjan Steinsson ²¹, Rosalind Ramsey-Goldman ²², Asad A Zoma ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Munther A Khamashta ²⁶, Graciela Alarcón ²⁷, Elisabet Svenungsson ²⁸, Ronald F Van Vollenhoven ²⁹, Cynthia Aranow ³⁰, Meggan Mackay ³¹, Guillermo Ruiz-Irastorza ³², Manuel Ramos-Casals ³³, S Sam Lim ³⁴, Murat Inanc ³⁵, Kenneth C Kalunian ³⁶, Soren Jacobsen ³⁷, Christine Peschken ³⁸, Diane Kamen ³⁹, Anca Askanase ⁴⁰, Chris Theriault ¹ and Vernon Farewell ², ¹Dalhousie University, Halifax, NS, Canada, ²University of Cambridge, Cambridge, United Kingdom, ³Universidy of Cambridge, Cambridge, United Kingdom, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁸Toronto Western Hospital, Toronto, ON, Canada, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹²Centre for Rheumatology, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, ¹⁵Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁶Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹State University of New York Downstate Medical Center, Brooklyn, NY, ²⁰UnC Kidney Centre, Chapel Hill, NC, ²¹Landspitali, University Hospital, Reykjavik, Iceland, ²²Northwestern University, Chicago, IL, ²³University of Glasgow, East Kilbride, United Kingdom, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶King's College London School of Medicine, London, United Kingdom, ²⁷University of Alabama at Birmingham, Birmingham, ²⁸Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²⁹Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ³⁰Feinstein Institute for Medical Research, Manhasset, NY, ³¹Feinstein Institute for Medical Research, New York, ³²Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Barakaldo, Spain, ³³Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ³⁴Emory University, Atlanta, GA, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶UC San Diego School of Medicine, LaJolla, CA, ³⁷Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁸University of Manitoba, Winnipeg, Canada, ³⁹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ⁴⁰Columbia University Medical Center, New York, NY
Background/Purpose: Although there is a large body of work on central nervous system (CNS) disease in SLE patients, involvement of the peripheral nervous system (PNS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].